These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 15721392

  • 1. Liposomal vasoactive intestinal peptide.
    Sethi V, Onyüksel H, Rubinstein I.
    Methods Enzymol; 2005; 391():377-95. PubMed ID: 15721392
    [Abstract] [Full Text] [Related]

  • 2. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles.
    Ashok B, Rubinstein I, Tsueshita T, Onyüksel H.
    Peptides; 2004 Aug; 25(8):1253-8. PubMed ID: 15350692
    [Abstract] [Full Text] [Related]

  • 3. Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension.
    Onyüksel H, Séjourné F, Suzuki H, Rubinstein I.
    Peptides; 2006 Sep; 27(9):2271-5. PubMed ID: 16621151
    [Abstract] [Full Text] [Related]

  • 4. Inhalable liposomal formulation for vasoactive intestinal peptide.
    Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W.
    Int J Pharm; 2008 Jun 05; 357(1-2):286-94. PubMed ID: 18328650
    [Abstract] [Full Text] [Related]

  • 5. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
    Stark B, Andreae F, Mosgoeller W, Edetsberger M, Gaubitzer E, Koehler G, Prassl R.
    Eur J Pharm Biopharm; 2008 Sep 05; 70(1):153-64. PubMed ID: 18555674
    [Abstract] [Full Text] [Related]

  • 6. Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
    Rubinstein I, Ikezaki H, Onyüksel H.
    Int J Pharm; 2006 Jun 19; 316(1-2):144-7. PubMed ID: 16580160
    [Abstract] [Full Text] [Related]

  • 7. Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity.
    Onyüksel H, Ashok B, Dagar S, Sethi V, Rubinstein I.
    Peptides; 2003 Feb 19; 24(2):281-6. PubMed ID: 12668213
    [Abstract] [Full Text] [Related]

  • 8. Stabilization of vasoactive intestinal peptide by lipids.
    Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S.
    J Pharmacol Exp Ther; 1998 May 19; 285(2):753-8. PubMed ID: 9580623
    [Abstract] [Full Text] [Related]

  • 9. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo.
    Rubinstein I, Ashok B, Tsueshita T, Onyüksel H.
    Peptides; 2005 Mar 19; 26(3):509-15. PubMed ID: 15652658
    [Abstract] [Full Text] [Related]

  • 10. Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo.
    Ikezaki H, Onyüksel H, Rubinstein I.
    Am J Physiol; 1998 Aug 19; 275(2):R588-95. PubMed ID: 9688697
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo.
    Séjourné F, Suzuki H, Alkan-Onyüksel H, Gao XP, Ikezaki H, Rubinstein I.
    Am J Physiol; 1997 Jul 19; 273(1 Pt 2):R287-92. PubMed ID: 9249562
    [Abstract] [Full Text] [Related]

  • 12. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles.
    Wernig K, Griesbacher M, Andreae F, Hajos F, Wagner J, Mosgoeller W, Zimmer A.
    J Control Release; 2008 Sep 10; 130(2):192-8. PubMed ID: 18601963
    [Abstract] [Full Text] [Related]

  • 13. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery.
    Stark B, Debbage P, Andreae F, Mosgoeller W, Prassl R.
    Biochim Biophys Acta; 2007 Mar 10; 1768(3):705-14. PubMed ID: 17204237
    [Abstract] [Full Text] [Related]

  • 14. Conformation and vasoreactivity of VIP in phospholipids: effects of calmodulin.
    Rubinstein I, Patel M, Ikezaki H, Dagar S, Onyüksel H.
    Peptides; 1999 Dec 10; 20(12):1497-501. PubMed ID: 10698126
    [Abstract] [Full Text] [Related]

  • 15. Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension.
    Rubinstein I.
    Expert Rev Cardiovasc Ther; 2005 Jul 10; 3(4):565-9. PubMed ID: 16076268
    [Abstract] [Full Text] [Related]

  • 16. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies.
    Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyüksel H.
    J Control Release; 2003 Aug 28; 91(1-2):123-33. PubMed ID: 12932644
    [Abstract] [Full Text] [Related]

  • 17. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.
    Dangoor D, Biondi B, Gobbo M, Vachutinski Y, Fridkin M, Gozes I, Rocchi R.
    J Pept Sci; 2008 Mar 28; 14(3):321-8. PubMed ID: 17924396
    [Abstract] [Full Text] [Related]

  • 18. Liposomal VIP potentiates DNA synthesis in cultured oral keratinocytes.
    Rubinstein I, Dagar S, Sethi V, Krishnadas A, Onyüksel H.
    Peptides; 2001 Apr 28; 22(4):671-5. PubMed ID: 11311738
    [Abstract] [Full Text] [Related]

  • 19. Encapsulation of VIP into liposomes restores vasorelaxation in hypertension in situ.
    Suzuki H, Noda Y, Gao XP, Séjourné F, Alkan-Onyuksel H, Paul S, Rubinstein I.
    Am J Physiol; 1996 Jul 28; 271(1 Pt 2):H282-7. PubMed ID: 8760186
    [Abstract] [Full Text] [Related]

  • 20. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis.
    Lajavardi L, Camelo S, Agnely F, Luo W, Goldenberg B, Naud MC, Behar-Cohen F, de Kozak Y, Bochot A.
    J Control Release; 2009 Oct 01; 139(1):22-30. PubMed ID: 19481575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.